We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Meta-analysis of Efficacy of Topotecan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01160185
Recruitment Status : Completed
First Posted : July 12, 2010
Last Update Posted : July 12, 2010
Information provided by:

Brief Summary:
This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix

Condition or disease Intervention/treatment
Cervical Intraepithelial Neoplasia Drug: paclitaxel Drug: cisplatin Drug: topotecan

Detailed Description:
Studies included in the meta-analysis were: GOG-0179, GOG-0204 & GOG-0169

Study Type : Observational
Actual Enrollment : 1 participants
Time Perspective: Retrospective
Official Title: Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix
Study Start Date : June 2009
Primary Completion Date : July 2009
Study Completion Date : July 2009

Group/Cohort Intervention/treatment
cisplatin Drug: cisplatin
cisplatin monotherapy
cisplatin + topotecan Drug: cisplatin
cisplatin monotherapy
Drug: topotecan
cisplatin + paclitaxel Drug: paclitaxel
Drug: cisplatin
cisplatin monotherapy

Primary Outcome Measures :
  1. Survival [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The search was designed to identify all clinical data published since the Cancer Care Ontario systematic review in 2006. The Cancer Care Ontario systematic review searched MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Library (Cochrane Database of Systematic Reviews (2006 Issue 1), and Cochrane Controlled Trials Register (2006 Issue 1)), the Canadian Medical Association Infobase, and the National Guidelines Clearinghouse. The conference proceedings of the American Society of Clinical Oncology (1995-2005) and the European Society of Medical Oncology (2002-2005) were also searched. The search was conducted on 18 December 2008.

Inclusion Criteria:

  • Randomised Clinical Trials or systematic reviews or meta-analyses
  • Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01160185

Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT01160185     History of Changes
Other Study ID Numbers: 114015
First Posted: July 12, 2010    Key Record Dates
Last Update Posted: July 12, 2010
Last Verified: July 2010

Additional relevant MeSH terms:
Carcinoma in Situ
Cervical Intraepithelial Neoplasia
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors